Andrew Hill

Overview

Best Publications

• Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis

  Ravindra K Gupta;Michael R Jordan;Binta J Sultan;Andrew Hill

  491
  Citations

• Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis

  Bryony Simmons;Jawaad Saleem;Andrew Hill;Richard D. Riley

  355
  Citations

• Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis.

  Ravindra K Gupta;Andrew Hill;Anthony W Sawyer;Alessandro Cozzi-Lepri

  353
  Citations

• Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response

  Bryony Simmons;Jawaad Saleem;Katherine Heath;Graham S. Cooke

  333
  Citations

• CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1 : results of the staccato randomised trial

  Jintanat Ananworanich;Angèle Gayet-Ageron;Michelle Le Braz;Wisit Prasithsirikul

  291
  Citations

• Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries

  Andrew Hill;Saye Khoo;Joe Fortunak;Bryony Simmons

  278
  Citations

• A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic?

  Victoria Pilkington;Toby Pepperrell;Andrew Hill

  266
  Citations

• Emergence of Drug Resistance in HIV Type 1-Infected Patients after Receipt of First-Line Highly Active Antiretroviral Therapy: A Systematic Review of Clinical Trials

  Ravindra Gupta;Andrew Hill;Anthony W. Sawyer;Deenan Pillay;Deenan Pillay

  251
  Citations

• Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.

  Willem D F Venter;Simiso Sokhela;Bryony Simmons;Michelle Moorhouse

  239
  Citations

• The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.

  Jose R Arribas;Andrzej Horban;Jan Gerstoft;Gerdt Fätkenheuer

  221
  Citations

• Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial.

  Rebekah L. Puls;Janaki Amin;Marcelo Losso;Praphan Phanuphak

  199
  Citations

• The future role of CD4 cell count for monitoring antiretroviral therapy

  Nathan Ford;Nathan Ford;Graeme Meintjes;Anton Pozniak;Helen Bygrave

  178
  Citations

• Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets.

  Brian Barr Godman;Anna Bucsics;Patricia Vella Bonanno;Wija Oortwijn;Wija Oortwijn

  164
  Citations

• The road to elimination of hepatitis C: analysis of cures versus new infections in 91 countries.

  Andrew M. Hill;Sanjay Nath;Bryony Simmons

  162
  Citations

• Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.

  Usman Arshad;Henry Pertinez;Helen Box;Lee Tatham

  157
  Citations

• Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial.

  Ulrik B.Ulrik Dragsted;Jan Gerstoft;Court Pedersen;Barry Peters

  156
  Citations

• Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?

  Andrew Hill;Sophie L Hughes;Dzintars Gotham;Anton L Pozniak

  151
  Citations

• The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?

  Marco Vitoria;Andrew Hill;Nathan Ford;Meg Doherty

  135
  Citations

• The Joint United Nations Programme on HIV/AIDS 95-95-95 targets: worldwide clinical and cost benefits of generic manufacture.

  Katherine Heath;Jacob Levi;Andrew Hill

  134
  Citations

• The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline.

  J R Arribas;N Clumeck;M Nelson;A Hill

  127
  Citations

• Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial.

  Anahita Sadeghi;Ali Ali Asgari;Alireza Norouzi;Zahedin Kheiri

  127
  Citations

• Improvement in vitamin D deficiency following antiretroviral regime change: Results from the MONET trial.

  Julie Fox;Barry Peters;Manyu Prakash;Jose Arribas

  123
  Citations

• Rapidly declining HIV infection in MSM in central London.

  Nneka Nwokolo;Andrew Hill;Alan McOwan;Anton Pozniak

  121
  Citations